Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 5056 participants.

Also called NCT07037459

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 5,056 participants (planned count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07037459
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czechia, Denmark, Finland, France, Germany, Greece, Hong Kong SAR China, Hungary, Italy, Japan, Mexico, Netherlands, Poland, Portugal, Puerto Rico, Romania, Slovakia, South Korea, Spain, Sweden, Switzerland, Taiwan, Türkiye, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07037459. Randomized; double masking; primary purpose treatment. Start 2025-06-25 (actual); primary completion 2028-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Acronym
MARITIME-HF
Condition
Heart Failure With Mildly Reduced Ejection Fraction
Condition
Obesity
Intervention (Drug)
Maridebart cafraglutide
Intervention (Drug)
Placebo
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct07037459
Content hash
eedddb95a87e887467e61a930d9f2114d7b49992ea2f3006878938a8b08620fa